CEO Executive AssistantTime management for pharma regulatory affairs is not a peripheral concern for pharmaceutical CEOs. It sits at the center of your organization’s most critical value-creation activities. Regulatory submissions, FDA interactions, and approval timelines determine when and whether your pipeline products reach patients and markets. The stakes are high enough that regulatory affairs can colonize your calendar if you allow it to, and high enough that inadequate oversight can cost your organization years of competitive advantage.
The challenge is calibration. Your regulatory affairs team is staffed with specialists who have domain expertise you cannot and should not try to replicate. Your role is not to review submission documents line by line or to manage the agency communication process operationally. Your role is to make the strategic decisions that only a CEO can make, to maintain the relationships that require CEO-level engagement, and to ensure that the regulatory function has the resources and organizational support it needs to perform at the highest level.
This article is a guide to building that calibrated involvement through deliberate time management for pharma regulatory affairs.
Understanding the CEO’s Unique Role in Regulatory Affairs
Time management for pharma regulatory affairs begins with a clear-eyed assessment of where CEO involvement creates genuine value and where it creates noise.
Where CEO Judgment Is Irreplaceable
There are specific decision points in the regulatory process where your involvement is not just appropriate but essential. These include: the decision to submit a New Drug Application (NDA) or Biologics License Application (BLA) and the strategic timing of that submission; decisions about how to respond to a Complete Response Letter (CRL) or other major FDA feedback; preparation for and participation in Type A or Type B meetings with the FDA where organizational leadership presence is expected or strategically valuable; communications with board, investors, and major partners about regulatory milestones and setbacks; and resource allocation decisions that affect the regulatory team’s capacity.
These are CEO-level decisions and engagements. They require your direct attention, your judgment, and in some cases your personal participation.
Where CEO Involvement Creates Problems
In contrast, CEO involvement in the operational details of regulatory affairs creates real costs. Reviewing submission document sections that your regulatory team is better equipped to evaluate, attending routine project management meetings for regulatory submissions, or becoming a decision node for questions that your Head of Regulatory Affairs should answer independently: all of these behaviors slow the regulatory process, undermine your team’s authority, and consume your time without proportionate benefit.
McKinsey research on executive effectiveness consistently identifies inappropriate level of involvement as a primary constraint on CEO impact. In pharmaceutical companies, where the regulatory function operates under severe time pressure, this constraint is especially costly.
Defining these boundaries clearly, and communicating them to your regulatory affairs leadership, is the foundational act of time management for pharma regulatory affairs.
Building Your Regulatory Update Cadence
Information architecture drives time management. If your regulatory affairs team knows exactly when and in what format they have your attention, they can manage their internal communication rhythms accordingly. If that structure does not exist, they will seek access whenever they feel the urgency of their work warrants it, which is often.
The Weekly Regulatory Briefing
Establish a standing weekly briefing with your Head of Regulatory Affairs. This should be a focused, 30-minute meeting that covers: any FDA communications received during the week and their strategic implications; upcoming regulatory milestones in the following two to four weeks; any emerging issues that may require CEO decision-making or awareness; and any agency relationship considerations that need CEO-level attention.
The weekly briefing is your primary regulatory information channel. Between these meetings, your Head of Regulatory Affairs manages the function operationally and escalates only when something meets the explicit criteria for immediate CEO engagement: a significant unexpected FDA communication, a safety issue with regulatory implications, or a situation that will require CEO-level response within 24 to 48 hours.
The Monthly Regulatory Portfolio Review
In addition to your weekly briefing, hold a monthly 60-minute regulatory portfolio review that covers your full regulatory pipeline. This includes: the status of all active submissions; the timeline for anticipated submissions in the coming 12 months; any regulatory strategy questions that require CEO input or alignment; and an assessment of agency relationship health for your key product areas.
The monthly portfolio review gives you the longer-range visibility you need for investor communications, board reporting, and strategic planning. It also surfaces strategic regulatory questions early enough that you have time to think through them deliberately rather than reactively.
Quarterly Regulatory Strategy Session
Once per quarter, hold a deeper regulatory strategy session with your Head of Regulatory Affairs, CMO, and Chief Scientific Officer. This two-hour session examines your regulatory strategy at the portfolio level: how submission timing aligns with your competitive positioning, how regulatory milestones integrate with your business development and commercial planning, and whether your regulatory strategy is optimally designed to support your organizational goals.
This quarterly session is where CEO-level strategic thinking contributes most distinctively to the regulatory function. It is the forum for asking the questions your regulatory specialists may not ask because they are focused on execution: are we submitting to the right markets in the right sequence, are we investing appropriately in regulatory science and agency relationships, and are there regulatory strategy choices we should reconsider in light of competitive or scientific developments?
Protecting Deep-Work Time During Submission Periods
Regulatory submission periods are among the most intense operational phases a pharmaceutical company experiences. The 12 months preceding a major NDA or BLA filing, and the months following submission while awaiting FDA review, generate extraordinary demands on organizational time and attention. For the CEO, managing your calendar during these periods requires explicit, proactive design.
Pre-Building Your Submission Period Calendar
When you know a major submission is 6 to 12 months away, begin designing your calendar around that event immediately. Identify the submission date and work backward. Approximately 90 days before submission, your involvement in regulatory strategy reviews will increase. In the final 30 days before submission, you should have time blocked for executive sign-off processes, board notification, and investor relations preparation.
After submission, block time for: FDA acknowledgment and filing review responses, preparation for any anticipated FDA requests for information, and preparation for the PDUFA date period including investor and partner communications.
If your calendar is not pre-built around these events, the submission period will generate reactive demands that fragment your focus and consume time you had committed to other priorities.
Protecting Two Deep-Work Blocks Per Week
Regardless of where you are in the regulatory cycle, protect a minimum of two 90-minute deep-work blocks per week. These blocks are non-negotiable. They are not available for regulatory update meetings, internal briefings, or investor calls. They are reserved for the kind of sustained strategic thinking that regulatory decisions at the CEO level require.
During a submission period, you may use these blocks to work through the strategic implications of potential FDA outcomes, to prepare for agency meetings, or to think through how different approval scenarios affect your commercial and organizational planning. The content changes with the context. The protection of the time does not.
Your executive assistant is the operational defender of these blocks. Brief your EA specifically on the importance of deep-work time protection during regulatory submission periods and give them the authority to decline meeting requests that encroach on these blocks without escalating to you for each individual decision.
For a comprehensive approach to structuring your calendar around strategic priorities, this guide on CEO calendar design provides the overarching framework.
Managing FDA Interactions at the CEO Level
Direct FDA interactions that involve CEO participation are high-stakes, high-preparation events. Managing your time around these interactions requires both preparation investment and post-meeting follow-through.
Preparation Investment
For any meeting where you will be present with FDA representatives, invest substantively in preparation. This does not mean reading every page of the briefing document your regulatory team prepares. It means understanding the strategic objectives of the meeting, the key positions your organization will advance, the likely areas of FDA inquiry, and the decisions or guidance you are seeking.
A focused two-hour preparation session with your Head of Regulatory Affairs and CMO, conducted several days before the meeting, is the appropriate investment level. This session gives you the strategic context you need to participate effectively without requiring you to replicate the technical preparation your regulatory specialists have already done.
CEO Roles in FDA Meetings
Be clear about your role in FDA meetings. In most cases, you are present to demonstrate organizational commitment to the program, to provide authoritative answers to questions about organizational strategy and resource commitment, and to reinforce the significance of the interaction at the leadership level. You are not the primary scientific or regulatory spokesperson; your Head of Regulatory Affairs and CMO carry those roles.
When you understand your specific role, you can contribute precisely rather than diffusely. That precision is both more effective in the meeting and less demanding of your preparation time.
Building the Regulatory Affairs Leadership Relationship
Your relationship with your Head of Regulatory Affairs is the most important variable in your time management equation for this function. A strong, confident Head of Regulatory Affairs who operates with appropriate authority significantly reduces the demands on your calendar. A Head of Regulatory Affairs who lacks confidence in their authority, or who operates in an environment where CEO involvement is unpredictable, will escalate more frequently and consume more of your time.
Investing in Your Head of Regulatory Affairs
Invest in this relationship explicitly. Meet with your Head of Regulatory Affairs at a level that goes beyond the weekly briefing: periodic one-on-one conversations about their professional development, their assessment of the organizational challenges they face, and their perspective on your regulatory strategy. This investment pays dividends in a leader who operates with more confidence and less need for CEO validation on operational decisions.
Establish the escalation criteria explicitly. Write down what you want brought to you immediately, what can wait for the weekly briefing, and what should be handled without CEO involvement. Review these criteria periodically and adjust based on experience. This ongoing calibration of the escalation system is itself a strategic investment in your time management.
For guidance on building the delegation relationship that supports this kind of functional leader empowerment, this framework for effective delegation applies directly to the regulatory affairs leadership context.
Using the Regulatory Function as a Strategic Intelligence Source
One frequently underutilized dimension of the CEO-regulatory affairs relationship is the regulatory team’s visibility into the competitive and scientific landscape. Your regulatory affairs team monitors FDA advisory committee proceedings, public dockets, guidance document updates, and agency decisions on competitor products. This information has significant strategic value.
Structure your monthly regulatory portfolio review to include a brief competitive and regulatory environment update. What are the agency trends that affect your programs? What have recent advisory committee meetings signaled about FDA thinking in your therapeutic areas? What regulatory decisions affecting your competitors are instructive for your own strategy?
Positioning your regulatory team as a source of strategic intelligence, not just operational compliance management, changes the nature of your engagement with the function and increases the return on the time you invest in it.
Conclusion: Time Management for Pharma Regulatory Affairs Requires Governance Design
Time management for pharma regulatory affairs, for a pharmaceutical CEO, is ultimately a question of governance architecture. You need a structured cadence that keeps you informed at the strategic level. You need pre-built calendar protection for submission period demands. You need deep-work time that is defended against operational incursion. And you need a Head of Regulatory Affairs who operates with the authority and confidence to manage the function without requiring continuous CEO reinforcement.
Build the weekly briefing, the monthly portfolio review, and the quarterly strategy session. Pre-block your calendar around major regulatory events. Protect deep-work time during submission periods. Invest in your regulatory affairs leadership relationship.
When your governance architecture is sound, time management for pharma regulatory affairs stops being a calendar problem and becomes a strategic advantage. You maintain the oversight the function requires, contribute the judgment only you can provide, and preserve your capacity for the full range of CEO responsibilities that your organization depends on you to fulfill.